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Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-dependent transcription
factor involved in many aspects of metabolism, immune response, and development. Total-
body deletion of the two Pparg alleles provoked generalized lipoatrophy along with severe
type 2 diabetes. Herein, we explore the appearance and development of structural and func-
tional alterations of the kidney, comparing Pparg null-mice to their littermate controls (carry-
ing Pparg floxed alleles). We show that renal hypertrophy and functional alterations with
increased glucosuria and albuminuria are already present in 3 weeks-old Pparg null-mice.
Renal insufficiency with decreased creatinine clearance progress at 7 weeks of age, with
the advance of the type 2 diabetes. At 52 weeks of age, these alterations are accompanied
by signs of fibrosis and mesangial expansion. More intriguingly, aged Pparg null-mice con-
comitantly present an anti-phospholipid syndrome (APS), characterized by the late appear-
ance of microthrombi and a mesangioproliferative pattern of glomerular injury, associated
with significant plasmatic levels of anti-β2- glycoprotein1 antibodies and renal deposition of
IgG, IgM, and C3. Thus, in line with the role of PPARγ in metabolic homeostasis, Pparg null-
mice first represent a potent model for studying the initiation and the development of diabetic
nephropathy. Second, and in relation with the important PPARγ activity in inflammation and
in immune system, these mice also highlight a new role for PPARγ signaling in the promo-
tion of APS, a syndrome whose pathogenesis is poorly known and whose current treatment
is limited to prevention of thrombosis events.
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Introduction
Diabetic nephropathy is one major complication of type 2 diabetes. In human, the injurious
effects of hyperglycemia are separated into macrovascular complications (coronary artery dis-
ease, peripheral arterial disease, and stroke) and microvascular complications (diabetic
nephropathy, neuropathy, and retinopathy). Diabetic nephropathy is currently the leading
cause of end-stage renal disease in many countries and it occurs in ~30% of people with type 1
diabetes and 25–40% of people with type 2 diabetes. Its progression has been described in 5
steps, from an initial renal hypertrophy and hyperfiltration phase, which then persist with the
occurrence of hyperglycaemia, followed by the appearance of microalbuminuria, the installa-
tion of progressive renal failure and finally an end-stage renal failure. Lack of satisfactory ani-
mal model has brought up the establishment of a list of criteria that should be met for tagging
a kidney pathology with either a progressive diabetic nephropathy or an advanced states of dia-
betic nephropathy (Animal Models of Diabetic Complications Consortium (AMDCC) (http://
www.amdcc.org).
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-dependent transcription
factor of the nuclear receptor superfamily, which plays a central role in adipogenesis and is
expressed in different compartments of the kidney at both the glomerular and tubular levels
[1]. In various rodent models of type 2 diabetes (db/db mice, obese Zucker rats, and OLETF
rats), treatment with thiazolidinedione (TZD)–a high-affinity synthetic ligand for PPARγ –not
only improves insulin resistance and glycemic control, but also ameliorates diabetic nephropa-
thy by inhibiting glomerular hypertrophy, reducing mesangial matrix expansion, and improv-
ing proteinuria and renal function [2]. On the other hand, TZD provokes substantial renal
sodium retention associated with edema and plasma volume expansion, the mechanisms of
which remain unclear (reviewed in Horita et al. [3]). In addition, a distinct direct action of
PPARγ in the kidneys was suggested by cell-specific deletion of Pparg in mouse macrophages,
which triggers the appearance of lupus nephritis signs [4].
While cell-specific Pparg deletion is useful for identifying its numerous cell- and tissue-spe-
cific activities, the overall systemic role of Pparg can be better appreciated upon total deletion.
Using an epiblast-specific Cre-mediated recombination of Pparg floxed alleles (Ppargfl), we gen-
erated total-body Pparg-null mice [5], hereafter called PpargΔ/Δ. These mice showed total
absence of adipose tissue, early development of severe type 2 diabetes, and remarkable meta-
bolic inflexibility that we explore in a separate report (Gilardi et al., manuscript in preparation).
In the present report, the early development of these severe metabolic alterations lead us to
examine PpargΔ/Δ for the presence of microvascular complications that are highly prevalent in
type 2 diabetes [6]. Altough the retina did not exhibit modifications that could be linked to
type 2 diabetes, a systematic analysis of the kidney at different time points along development
and aging identified the first marks of glomerular and tubular functional alterations as early as
seven weeks of age, parallel to the development of the severe type 2 diabetes. Importantly, we
demonstrate that aging mice developed an anti-phospholipid syndrome.
Materials and methods
Animals and clinical parameters
Animal care and treatments were performed in agreement with the guidelines established by
the European Community Council Directives (86/609/EEC) and were authorized by the com-
mission for animal experimentation of the cantonal veterinary services (Canton of Vaud).
When needed, mice were sacrificed using CO2 inhalation. Genotype denomination follows as
far as possible, the rules recommended by the Mouse Genome Database (MGD) Nomenclature
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Committee. Construction of the PPARγ floxed allele (initially called PPARγL2, hereafter called
Ppargfl, and the Pparg-null allele resulting from Cre recombination (PPARγL-), hereafter called
PpargΔ) has previously been described [7]. The PPARγ null mice obtained via Pparg epiblast-
specific deletion have been previously reported [5]. Briefly, since homozygous PPARγ-/- mice
show an embryonic lethal phenotype due to a placental defect [5, 8], we crossed SOX2CREtg/+
transgenic mouse strain with mice homozygous for the Pparg floxed allele (Ppargfl/fl) to gener-
ate epiblast-specific deletion, generating Ppargfl deletion in all cells participating to the embryo
development whilst preserving PPARγ expression in the trophoblast [5]. Normal placenta
development allows SOX2CREtg/+PpargemΔ/Δ (hereafter called PpargΔ/Δ) pups to be born.
Pparg expression is totally undetectable in PpargΔ/Δ embryos as well as in various adult tissues
(including liver, kidney, and bones; data not shown). The control littermates (CTL) have no
SOX2CRE transgene and two functional Pparg alleles (Ppargfl/+). Both male and female have
been used throughout the study, except for the 52 week-old time point, for which only female
were available due to a relative earlier death of male mice.
Functional parameters were evaluated at the Mouse Metabolic Evaluation Facility (MEF) of
the University of Lausanne. Urinary measurements were done using spot urines or 24h urine
collection from metabolic cages. Urinary albumin and glucose were evaluated with Albuwell
M ELISA kit (Exocell, USA) and QuantiChromTM Glucose Assay Kit (BioAssay System, USA),
respectively. At sacrifice, kidneys were rapidly snap-frozen or put in PFA 4% for the subse-
quent embedding in paraffin.
Detection of autoantibodies
Plasma levels of anti-nuclear antibodies (ANAs) and anti-dsDNA IgGs were measured by
commercially available ELISAs (Alpha Diagnostic International, USA). Antibodies anti β2-gly-
coprotein1 were determined by ELISA, coating a 96 well-plate with 1μg/well of recombinant
mouse β2-glycoprotein1 (6575-AH-050, R&D Systems) overnight at 4˚C. After blocking,
mouse plasma samples (dil 1:100) were loaded and incubated at 37˚C for 1h. The detection
was done with HRP-conjugated anti mouse IgG-Fc antibody and TMB as substrate (Bethyl
Laboratoires, USA).
Angiography for retinal vessels
PpargΔ/Δ mice often showed corneal problems such as opacity due to the lack of Meibomian
glands (data not shown). Thus, to attempt to maintain a transparency of the cornea, the ani-
mals were treated with Vismed for 7 days before investigating the eye fundus. Before each fluo-
rescein angiography (FA), 28–32 week old mice were anesthetized by intraperitoneal injection
of a solution of ketamine/xylazine (66.7 mg/kg / 9.88 mg/kg). Upon full dilation after instilla-
tion of Tropicamide (0.5%, SDU Faure/The´a) and Phenylephrine hypochloride (2.5%, Bausch
Lomb Minims), animals were placed onto the positioning table. Then an ophthalmic gel
(Goniovisc 2.5%, HUB Pharmaceuticals) was applied on the eye and the objective was oriented
for imaging. Just after intraperitoneal injection of a solution of fluorescein (10 μL of 1% fluo-
rescein in saline per gram of body weight), videos of the FA were recorded using a retinal
imaging system allowing a high imaging resolution through a specific objective for mice
(Micron III, Phoenix Research Labs, USA). Images were then extracted at early (3 min) and
late (> 6 min) time-points and analyzed.
Histology and morphometry
For histological analysis, paraffin sections were stained with haematoxylin and eosin (HE),
periodic acid-Schiff (PAS), Silver methenamine, and Masson’s trichrome, according to routine
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protocols. Glomerular cross sectional area was assessed by tracing along the outline of the glo-
merular tuft of 60–90 glomeruli per mouse. For specific immunohistochemical staining for
collagen IV deposition and macrophage infiltration, paraffin kidney sections were incubated
overnight at 4˚C with the following primary antibodies: rabbit anti collagen IV (dil 1:400,
2150–1470, AbD Serotec, Germany) and rat anti F4/80 (dil 1:800, ab6640, Abcam, USA).
HRP-conjugated secondary antibodies were then applied, followed by DAB (Vector Laborato-
ries, USA) as the chromogen. After counterstaining with haematoxylin, all the sections were
examined by light microscopy (Microscope Zeiss Imager A1, Carl Zeiss Ltd., United King-
dom) and images were collected at 40x magnification. Collagen IV, expressed as a percentage
of stained area, and F4/80 quantification, expressed as number of positive cells/glomerular
cross-section, were then evaluated in 40–60 glomeruli from each section. Expression of colla-
gen IV in tubulointerstitium was instead measured in 20x images in the entire cortical area.
IgG, IgM and C3 were stained by Fc-specific anti mouse IgG, μ-chain specific anti mouse
IgM (FITC conjugated, Sigma, USA), and anti C3 antibody (ab11862, Abcam), respectively.
Real-time quantitative PCR
Total RNA was isolated after homogenisation in TRI-Reagent (Ambion, Thermo Fisher Scien-
tific Inc.) and extraction with RNeasy Mini Kit (Qiagen). Gene expression was analysed by
real-time quantitative PCR (FastStart Universal SYBR Green Master, Roche, USA) in a Strata-
gene MX3005P Detection System (Agilent Technologies, USA). Ribosomal protein S9 (RPS9)
was used as housekeeping gene. Primer sequences are available upon request.
Statistical analysis
Values, expressed as mean ± SEM, were analysed using Prism 5.0 (GraphPad Software, USA).
Student’s t test, or two-way ANOVA with Bonferroni post-test for multiple group comparisons
were used to assess statistical significance. A P value <0.05 was considered statistically
significant.
Results
Lack of retinal damages in PpargΔ/Δ mice
Diabetic retinopathy is a microvascular complication of diabetes. It is characterized by various
retinal lesions and represents the leading cause of blindness in the working population [6].
Considering the severity of type-2 diabetes in PpargΔ/Δ mice, we explored the possible develop-
ment of diabetes associated retinal diseases, using fluorescein injection in the periphery. As
compared to control mice, no morphological abnormalities or leakage of the dye were
observed in mutant mice at 28 weeks suggesting the presence of an intact inner blood-retinal
barrier (S1 Fig). Similar observations were obtained in 46 weeks old mice (data not shown)
indicating that PpargΔ/Δ mice do not develop diabetic retinopathy.
PpargΔ/Δ mice present early signs of glomerular nephropathy
The appearance of renal alterations in PpargΔ/Δ mice was in contrast precocious and obvious.
At the time of weaning (3 weeks), PpargΔ/Δ mice exhibited metabolic disorders with elevated
glycemia in the fed state (Table 1). At the same age, plasma creatinine was unchanged, but
PpargΔ/Δ mice presented renal hypertrophy, increased glucosuria, and 5.6-fold higher albumin-
uria compared to control mice, suggesting that kidney functionality was already altered. At 7
weeks of age, evaluation of young mice in metabolic cages revealed significantly increased
water intake and urinary output compared to control mice (Table 1). At this time-point,
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severely impaired PpargΔ/Δ renal function was based on increased plasma creatinine and urea
nitrogen, and reduced creatinine clearance (40% that of littermate controls). Moreover, 24-hour
urinary collection revealed massive glucosuria and 16-fold higher albuminuria in PpargΔ/Δ mice
compared to controls (Table 1). The marked glucosuria led to osmotic diuresis, largely explain-
ing the high urinary output, while the concomitant albuminuria reflected glomerular damages.
Finally, PpargΔ/Δ mice showed greater sodium and potassium elimination compared to control
mice. This may be partly due to the hyperphagia of the lipodystrophic mice, which showed very
low circulating leptin. However, the difference remained important after correction per gram of
food intake, pointing to a decrease in tubular reabsorption (S2 Fig).
We next performed systematic histopathology analyses of the kidneys of PpargΔ/Δ mice at
different time-points. Quantitative analyses of kidney sections at 3, 7, and 15–20 weeks of age
revealed an age-associated increase of the glomerular cross-sectional area in PpargΔ/Δ mice. At
7 weeks of age, this area was already significantly higher compared to control littermates (Fig
1A and 1B). At 15–20 weeks of age, males showed glomerular lesions with moderate-to-severe
widening of the mesangial areas, together with moderate mesangial cell proliferation. Females
showed similar glomerular lesions at this age, although the changes were generally less severe
(Fig 1C). At this time-point, PpargΔ/Δ mice did not exhibit nodular glomerulosclerosis and
there were no specific findings in the tubulointerstitial compartment.
Thus, within the context of severe type 2 diabetes, the renal functional alterations and
histological modifications in PpargΔ/Δ mice were consistent with an early stage of diabetic
nephropathy.
Chronic kidney damages in PpargΔ/Δ ageing mice associate diabetic
nephropathy and antiphospholipid syndrome
Searching for specific signs of diabetic nephropathy, we evaluated the evolution of the lesions
with increasing age. At 52 weeks, PpargΔ/Δ mice exhibited altered renal functions based on
Table 1. Functional renal parameters of control and PpargΔ/Δ mice at 3 and 7 weeks of age.
Parameters CTL PpargΔ/Δ P value
3 weeks
Body weight (g) 12.36 ± 0.39(N = 7) 8.30 ± 0.44(N = 5) <0.0001
Glycemia (mmol/L) 10.05 ± 0.25(N = 11) 15.97 ± 2.20(N = 10) 0.0113
Total kidney w./body w. (x100) 1.24 ± 0.03(N = 7) 1.69 ± 0.06(N = 5) <0.0001
Plasma creatinine (μmol/L) 10.4 ± 0.24(N = 10) 11.2 ± 0.9(N = 8) 0.4088
Glucosuria/creatininuria (mg/mg) 2.76 ± 0.39(N = 6) 7.16 ± 1.91(N = 4) 0.0241
Urine albumin/creatinine (μg/mg) 53.35 ± 7.77(N = 6) 296.50 ± 87.31(N = 4) 0.0082
7 weeks
Body weight (g) 23.68 ± 0.28(N = 7) 23.02 ± 0.82(N = 6) 0.4383
24h water intake (ml) 5.17 ± 0.43(N = 7) 30.51 ± 0.78(N = 7) <0.0001
24h urinary output (ml) 1.05 ± 0.10(N = 7) 26.33 ± 1.3(N = 6) <0.0001
Plasma Urea Nitrogen (mmol/L) 8.0 ± 1.10(N = 5) 11.10 ± 1.10(N = 4) 0.0043
Plasma creatinine (μmol/L) 8.77 ± 0.57(N = 7) 19.61 ± 1.45(N = 7) <0.0001
Creatinine clearance (ml/min) 0.498 ± 0.060(N = 7) 0.189 ± 0.025(N = 6) 0.0009
Urine glucose (mg/24h) 1.64 ± 0.15(N = 7) 2273.03 ± 144.30(N = 6) <0.0001
Urine albumin (μg/24h) 62.86 ± 8.78(N = 4) 1025.28 ± 52.03(N = 4) <0.0001
Functional parameters of control (CTL) and PpargΔ/Δ mice at 3 and 7 weeks of age. Values are expressed as means ± SEM; N = number of animals; w. =
weight.
doi:10.1371/journal.pone.0171474.t001
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renal hypertrophy, plasma creatinine, and albuminuria (Fig 2A–2D) as well as extensive glo-
merular changes, including increased glomerular size (Fig 2E and 2F). Periodic acid-Schiff
(PAS) staining revealed increased mesangial matrix deposition and mesangial hypercellularity
and some glomeruli adopted a lobular shape. Moreover, both PAS and silver methenamine
stainings suggested increased glomerular basement membrane thickness (Fig 2E).
Fig 1. Early histomorphometric damages in PpargΔ/Δ kidney. (A) Representative images of paraffin
kidney sections stained with HE in control (CTL) and PpargΔ/Δ mice (γΔ/Δ) at different ages. Scale bar
represents 100μm (B) Quantitative analysis of glomerular cross-sectional area in control and PpargΔ/Δ mice. 3
weeks: 5 controls and 5 PpargΔ/Δ P>0.05. 7 weeks: 6 controls and 4 PpargΔ/Δ P<0.0001. 15/20 weeks
females: 4 controls and 4 PpargΔ/Δ P<0.0001. 15/20 weeks males: 3 controls and 3 PpargΔ/Δ P<0.0001 Data
are expressed as mean ± SEM. ***P<0.001 PpargΔ/Δ vs. control littermates (C) Representative sections of
kidney sections from male and female PpargΔ/Δ mice and littermate controls stained with periodic acid-Schiff
(PAS). Scale bar represents 100μm.
doi:10.1371/journal.pone.0171474.g001
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Diabetic nephropathy is generally characterized by tubulointerstitial fibrosis, and accu-
mulation of extracellular matrix components in the glomerular basement membrane and
Fig 2. Chronic functional and histological damages in ageing PpargΔ/Δ kidney. Indicated parameters and
histological studies were performed in 52 weeks old control (CTL) and PpargΔ/Δ (γΔ/Δ) mice. (A) Body weight (6
controls and 9 PpargΔ/Δ P = 0.0002), (B) renal hypertrophy as evaluated by the ratio total kidney weight over
total body weight (X100) (6 controls and 9 PpargΔ/Δ P<0.0001), (C) plasma creatinine (6 controls and 7 PpargΔ/Δ
P = 0.0384), (D) albuminuria (7 controls and 9 PpargΔ/Δ P<0.0001) (E) Representative images of paraffin kidney
sections stained with haematoxylin and eosin (HE), Periodic Acid Shiff (PAS), Silver methenamine (SV), and
Masson’s trichrome (MT). Scale bar represents 100μm. (F) glomerular cross-sectional area in 52 weeks female
mice (4 controls and 5 PpargΔ/Δ P = 0.0011). Data in the graphs corresponds to the mean ± SEM. *P<0.05,
**P<0.01, ***P<0.001 PpargΔ/Δ vs. age matched control littermates.
doi:10.1371/journal.pone.0171474.g002
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mesangium [9, 10]. Real-time qPCR—revealed moderate but significant increase in collagen I
and III expression at 7 weeks (S3 Fig). In aged PpargΔ/Δ mice, immunohistochemistry for colla-
gen IV (Fig 3A) and the increased renal expressions of collagen I, vimentin, and endothelin1
(Fig 3B) suggested that fibrosis continued throughout aging, consistent with the concomitant
mesangial expansion.
Intriguingly the kidneys of aged PpargΔ/Δ mice showed the appearance of nodular lesions
consisting of accumulated amorphous material within numerous glomeruli. The lesions were
strongly PAS-positive, non-argyrophilic, negative for Congo red staining excluding amyloid
deposition (data not shown), and a Masson’s trichrome staining pattern indicating presence of
intracapillary thrombi (Fig 2E). The incidence and large size of the thrombi led us to suspect
an antiphospholipid syndrome (APS)–i.e., an autoimmune disease diagnosed based on clinical
presence of thrombotic events and persistent positivity for antiphospholipid antibodies, partic-
ularly anti-β2-glycoprotein1 [11, 12]. The kidney is a major target of APS, with potential
thrombosis at any level [12, 13]. In line with APS criteria, 52-week-old PpargΔ/Δ mice showed
renal thrombosis and significantly elevated plasma levels of anti-β2-glycoprotein 1 antibodies
(Fig 3C).
APS is classified as primary when it occurs alone, and as secondary when it occurs in associ-
ation with other autoimmune disorders, most frequently systemic lupus erythematosus (SLE).
Considering that cell-specific Pparg deletion in macrophages causes the appearance of SLE
signs [4], we further extended our investigations to search for renal signs of SLE. No changes
in IgG or IgM were observed at 25 weeks of age (data not shown). However, 52-week-old
PpargΔ/Δ mice showed strong glomerular deposition of IgG, IgM, and C3 (Fig 4A). Consis-
tently, 52-week-old PpargΔ/Δ mice showed increased circulating anti-dsDNA IgGs and antinu-
clear antibodies (ANAs) compared to control littermates (Fig 4B), further confirming the
autoimmune disorder [14]. Finally, the associated inflammation [15] was indicated by a statis-
tically significant upregulation of IL1β and MCP1 in the kidneys of 52-week-old PpargΔ/Δ
mice, whereas TNFα remained unchanged (Fig 4C). Accordingly, increased macrophage infil-
tration was detected in both the glomerular (Fig 4D) and tubulointerstitial compartments
(Fig 4E).
Discussion
In summary, this report highlights two major kidney features of PpargΔ/Δ mice. The first obser-
vation in this model of total lipodystrophy was that early signs of type 2 diabetes led to early
alterations of kidney function, which progressively and rapidly worsened into renal insufficiency
with massive albuminuria. An association between lipodystrophy and diabetic nephropathy has
been previously reported in lipoatrophic A-ZIP/F-1 mice [16, 17] and in ob/ob mice carrying
deletion of Pparg2 (a Pparg splice variant mainly expressed in adipose tissue) [18]. The present
lack of a satisfactory animal model for diabetic nephropathy has led the research community to
propose a series of criteria that a model should meet to be useful in translational research (Ani-
mal Models of Diabetic Complications Consortium; AMDCC) [10]. While PpargΔ/Δ mice fulfil
the criteria of functional alterations, they lack some histopathological features required to fully
mimic human diabetic nephropathy. However, we believe that this model is particularly perti-
nent for mechanistic studies of the initial perturbations in diabetic nephropathy.
The second feature noted was the appearance in aged mice of APS in association with signs
of lupus nephritis. To our knowledge, the PpargΔ/Δ mouse is the first mouse model that sponta-
neously develops APS, representing a new tool for exploring the unsolved questions related to
APS pathogenesis. The importance of PPARγ in immunity and inflammation is well proven
[19, 20] and both aspects may be of importance for APS development.
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Fig 3. Immunohistochemistry and gene expression of fibrosis markers in kidney of ageing PpargΔ/Δ
mice, and plasmatic levels of anti-β2-glycoprotein1 antibodies. 52 weeks old control (CTL) and PpargΔ/Δ
(γΔ/Δ) animals were analyzed for the following parameters: (A) Top panels: Kidney Immunohistochemistry
for collagen IV (Col-IV). Positive staining is in brown. Scale bar represents 100μm. Bottom panels: quantification
of Col-IV deposition at glomerular levels (4 controls and 4 PpargΔ/ΔP = 0.0067) and tubulointerstitial levels
(4 controls and 4 PpargΔ/Δ P = 0.0238), (B) Evaluation by RT-qPCR of the following gene expression in the
kidney of CTL (N = 5) and PpargΔ/Δ (N = 7) mice: collagen I (Col-I, P = 0.0081), collagen III (Col-III, P = 0.1441,
not significant), vimentin (P = 0.0083) and Endothelin 1 (P = 0.0015). Results are reported as fold change
with respect to control levels, which were arbitrarily set to 1. (C). Plasma levels of antibodies against the β2-
glycoprotein1 (6 controls and 10 PpargΔ/ΔP = 0.0233). Data in the graphs corresponds to the mean ±SEM.
*P<0.05, **P<0.01 PpargΔ/Δ vs. age matched control littermates.
doi:10.1371/journal.pone.0171474.g003
Diabetic nepthopathy and antiphospholipid syndrome in PPARγ-null mice
PLOS ONE | DOI:10.1371/journal.pone.0171474 February 9, 2017 9 / 14
Fig 4. Renal immune complex deposition and inflammation in old PpargΔ/Δ mice. (A)
Immunofluorescence for IgG (left panel, green staining), IgM (middle panel, green staining), and C3 (right
panel, red staining) deposition on frozen kidney sections of 52 weeks old control (CTL) and PpargΔ/Δ (γΔ/Δ)
mice. The nuclei are labeled in blue (DAPI). Scale bar represents 50μm. (B) Plasma levels of anti dsDNA IgGs
(9 controls and 13 PpargΔ/Δ P = 0.0003) and ANAs (6 controls and 9 PpargΔ/Δ P = 0.0098). (C) Evaluation of
IL1β (5 controls and 7 PpargΔ/Δ P = 0.001), MCP1 (5 controls and 7 PpargΔ/Δ P = 0.0079), and TNFα (5
controls and 6 PpargΔ/Δ P = 0.799, not significant) gene expression by RT-qPCR in 52 weeks old control and
PpargΔ/Δ animals. Results are reported as fold change with respect to control levels arbitrarily set to 1. Data
are the mean ± SEM (D) The two left panels are representative images of F4/80 immunohistochemistry in
glomeruli (scale bar represents 50μm). The right panel is a relative quantification of positive cells (stained in
brown; 5 controls and 7 PpargΔ/Δ P = 0.0062). (E) Representative images of F4/80 immunohistochemistry in
tubulointerstitial areas (scale bar represents 100μm) of 52 weeks old control and PpargΔ/Δ mice. *P<0.05,
**P<0.01 PpargΔ/Δ vs. control littermates.
doi:10.1371/journal.pone.0171474.g004
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The link between APS and autoimmune diseases is well established. Anti-phospholipid
antibodies are indeed widely considered as the main actors in inducing the pathological coagu-
lation process, leading to thrombosis, the devastating clinical issue in APS that can potentially
affect any organ in the body. In humans, while the causes of primary APS are poorly known
[13], the main cause of secondary APS is SLE, affecting around 30% of APS patients [21]. Kid-
ney alterations appear equally in primary and secondary APS. In both forms, patient treatment
is mainly limited to preventing thrombosis events. Consistent with the role of PPARγ in
inflammation and immunity, TZD treatment is known to be protective against complications
such as atherosclerosis and renal disease in various murine SLE models [22–24]. Our results
raise the question whether TZD treatment would also help in controlling APS complication in
kidney.
The link between APS and inflammation is in contrast more controversial. Some classifica-
tions consider the lack of inflammatory context as one criteria for APS diagnostic [25], whereas
recent reports insist on the pro-inflammatory status of APS [26, 27]. Recently, NF-kB and c-
Jun/AP-1 have been involved in the pathogenic role of β2-glycoprotein1- antibodies as impor-
tant mediators in the production of prothrombotic and proinflammatory molecules in endothe-
lial cells and monocytes [28]. Along this line, specific deletion of PPARγ in macrophages led to
a dramatic increase in basal levels of proinflammatory molecules, possibly through NF-kB-
mediated signalling [29]. According to our findings, and albeit one limitation of our study is the
lack of human studies, we hypothesise that PPARγ whole body deletion affects macrophage
functions, resulting in a deficient clearance of injured cells, a deleterious alteration of the nor-
mal physiological levels and function of the β2-glycoprotein1- antibody complexes, thereby pro-
moting a prothrombotic status. Such a mechanism would possibly contribute to primary APS,
considering that while heterogeneous antiphospholipid antibodies can be transiently detected
after infections in the general population, the mechanisms leading to their permanent circula-
tion are still unknown [13].
One particular feature of our model, and one of its limitation, is the association of a severe
type 2 diabetes and sign of lupus nephritis. In humans, although the overlap between SLE and
type-2 diabetes is uncommon (0.8%) [30], emerging evidences point to an increased predispo-
sition of developing insulin resistance and metabolic syndrome in SLE patients and in mouse
models [31, 32]. This combination of diseases and the double jeopardy of subsequent compli-
cations underscore the need to identify novel and safe treatments. Finally, considering that
only two cases of human partial lipodystrophy associated with antiphospholipid and anticar-
diolipin antibodies were reported [33, 34], it is likely that specific PPARγ deletion at cellular
level, rather than the lipoatrophy, is fundamental in favoring the autoimmune response.
In conclusion, the dual kidney phenotype observed herein reflects two major systemic
activities of PPARγ, one relating to metabolic homeostasis (specifically, glucose and lipid
metabolism) and the other to immunity and inflammation. The intricate renal consequences
of the total lack of PpargΔ/Δ undescore the need to comprehensively understand PPARγ sys-
temic actions when this nuclear receptor is targeted. In clinical practice TZDs are known to
ameliorate many aspects of diabetic as well as non-diabetic nephropathy [1]. Further research
should focus on the immunological aspect, particularly with regards to the present poor palette
of therapeutic approaches for APS.
Supporting information
S1 Fig. Evaluation of vascular integrity in the retina of PpargΔ/Δ mice. Eye fundus of (A, B)
control (CTL) and (C, D) PpargΔ/Δ (γΔ/Δ) mice. No distinct morphological alterations are
observed between the two groups. Fluorescein angiography (FA) shows a normal vascular
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pattern and no leakage of the vessels in (C’, D’) PpargΔ/Δ mice compared to (A’, B’) control lit-
termates. Nonetheless, a certain diffusion of the signal occurs in the KO mice due to some
opacity of the cornea.
(TIF)
S2 Fig. Evaluation of sodium and potassium clearance and fractional excretion in 7 weeks
old PpargΔ/Δ mice. Values are expressed as means ± SEM; Natriuria: 7 controls and 6 PpargΔ/Δ
P = 0.0028; Plasma Sodium: 7 controls and 7 PpargΔ/Δ P = 0.0216; Clearance Sodium: 7 con-
trols and 6 PpargΔ/Δ P<0.0001; FE (Sodium): 7 controls and 6 PpargΔ/Δ P = 0.0001; Kaliuria: 7
controls and 6 PpargΔ/Δ P = 0.0418; Plasma Potassium: 7 controls and 7 PpargΔ/Δ P = 0.013;
Clearance Potassium: 7 controls and 6 PpargΔ/Δ P = 0.0013; FE (Potassium): 7 controls and 6
PpargΔ/Δ P = 0.0001. FE: fractional excretion. P<0.05, P<0.01, P<0.001 PpargΔ/Δ vs. con-
trol littermates
(TIF)
S3 Fig. Fibrosis and inflammation parameters in 7 weeks old PpargΔ/Δ mice. (A) RT-qPCR
in 7 weeks old control (CTL, N = 5) and PpargΔ/Δ (γΔ/Δ; N = 5) animals to evaluate gene expres-
sion of collagen I (Col–I, P = 0.0062), collagen III (Col–III; P = 0.0165) and vimentin (P =
0.0299). Results are reported as fold change with respect to control levels, which were arbi-
trarily set to 1. Data show mean ± SEM. (B) Evaluation by RT-qPCR in 7 weeks old control
(N = 4) and PpargΔ/Δ (N = 5) animals of gene expression of IL1β (P = 0.1885; not significant)
and MCP1 (P = 0.0312). Results are reported as in A. P<0.05 and P<0.01 PpargΔ/Δ vs. con-
trol littermates.
(TIF)
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